GPCR STRUCTURE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, STRUCTURE THERAPEUTICS INC reported revenue of n/a, net income of −$106M and diluted EPS of −$0.49; for the fiscal year ended December 2025 revenue was n/a.
GPCR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$177M, net income −$141M (margin n/a), EPS −$0.80
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$158M, net income −$123M (margin n/a), EPS −$0.78
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$103M, net income −$89.6M (margin n/a), EPS −$0.81
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$52.6M, net income −$51.3M (margin n/a), EPS −$5.51
GPCR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$106M, EPS −$0.49
- Quarter ended Mar 31, 2026: revenue n/a, net income −$76.0M, EPS −$0.35
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $33.0M, EPS $0.20
- Quarter ended Sep 30, 2025: revenue n/a, net income −$65.7M, EPS −$0.37
- Quarter ended Jun 30, 2025: revenue n/a, net income −$61.7M, EPS −$0.36
- Quarter ended Mar 31, 2025: revenue n/a, net income −$46.8M, EPS −$0.27
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$36.5M, EPS −$0.21
- Quarter ended Sep 30, 2024: revenue n/a, net income −$34.0M, EPS −$0.20
- Quarter ended Jun 30, 2024: revenue n/a, net income −$26.0M, EPS −$0.18
- Quarter ended Mar 31, 2024: revenue n/a, net income −$26.0M, EPS −$0.19
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$24.5M, EPS −$0.15
- Quarter ended Sep 30, 2023: revenue n/a, net income −$23.9M, EPS −$0.21
- Quarter ended Jun 30, 2023: revenue n/a, net income −$23.3M, EPS −$0.20
- Quarter ended Mar 31, 2023: revenue n/a, net income −$18.0M, EPS −$0.25
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$11.9M, EPS −$1.16
- Quarter ended Sep 30, 2022: revenue n/a, net income −$12.4M, EPS −$1.27
- Quarter ended Jun 30, 2022: revenue n/a, net income −$13.9M, EPS −$1.64
- Quarter ended Mar 31, 2022: revenue n/a, net income −$13.1M, EPS −$1.44
GPCR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$222M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$117M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$79.5M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$46.1M, share buybacks n/a
GPCR balance sheet
- Jun 30, 2026: cash $273M, total assets $1.43B, total liabilities $71.0M, shareholders' equity $1.35B
- Mar 31, 2026: cash $316M, total assets $1.51B, total liabilities $61.0M, shareholders' equity $1.45B
- Dec 31, 2025: cash $800M, total assets $1.58B, total liabilities $67.5M, shareholders' equity $1.52B
- Sep 30, 2025: cash $103M, total assets $832M, total liabilities $62.1M, shareholders' equity $770M
- Jun 30, 2025: cash $147M, total assets $816M, total liabilities $44.4M, shareholders' equity $772M
- Mar 31, 2025: cash $152M, total assets $867M, total liabilities $41.9M, shareholders' equity $825M
- Dec 31, 2024: cash $170M, total assets $903M, total liabilities $38.5M, shareholders' equity $865M
- Sep 30, 2024: cash $172M, total assets $933M, total liabilities $36.4M, shareholders' equity $897M
Is GPCR profitable?
No. STRUCTURE THERAPEUTICS INC lost $215M over the last four quarters.
What is GPCR's EPS?
Diluted earnings per share over the last four quarters were −$1.01; −$0.49 in the latest quarter.